A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
By L. Kappos, E. Radue, P. O'Connor, C. Polman, R. Hohlfeld, Peter A. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, Lixin Zhang-Auberson and 1 more. New England Journal of Medicine, 2010
2,522 citations recorded by the source corpus.
Subfields: Molecular Biology, Pathology and Forensic Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/273df492f5330f45070c2fb1b9dba0a85c2210d9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pathology and Forensic Medicine
Citations in the corpus
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis (2010, background): “5 mg dose; cell counts remained stable for the entire treatment perio”
- Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. (2012, neutral): “Any serious adverse event 86 (21) 74 (18) 65 (16)”
- Immune responses to stroke: mechanisms, modulation, and therapeutic potential. (2020, background): “There are two FDA-approved immunomodulatory drugs with extensive safety records that may be beneficial in stroke: Fingolimod, a sphingosine-1 phosphate receptor modulator that prevents lymphocyte egress from lymph nodes, was approved by the FDA for multiple sclerosis (177).”